| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | NK1; BY55; NK28 |
| Entrez GeneID | 11126 |
| clone | 1D4A4 |
| WB Predicted band size | 19.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD160 (AA: 25-155) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于CD160抗体的代表性文献(信息基于公开研究归纳)：
1. **文献名称**：*CD160 signaling enhances NK cell responses against tumors*
**作者**：Giulia Costa et al.
**摘要**：研究揭示了CD160抗体通过增强自然杀伤(NK)细胞的细胞毒性和细胞因子分泌能力，提升其对肿瘤细胞的杀伤效果，提示其在癌症免疫治疗中的潜力。
2. **文献名称**：*CD160 regulates CD8+ T cell exhaustion in chronic viral infection*
**作者**：Maud Favier et al.
**摘要**：该文献发现，在慢性病毒感染模型中，阻断CD160信号通路可逆转CD8+ T细胞的耗竭状态，恢复其抗病毒功能，为治疗慢性感染提供新策略。
3. **文献名称**：*CD160 interaction with HVEM promotes tumor immune evasion*
**作者**：Nathalie Anfossi et al.
**摘要**：研究显示，肿瘤细胞通过HVEM-CD160通路抑制NK细胞活性，而CD160抗体可阻断此相互作用，逆转免疫抑制微环境，抑制肿瘤生长。
4. **文献名称**：*CD160 as a novel checkpoint in autoimmune diseases*
**作者**：Sylvia Caillat-Zucman et al.
**摘要**：该研究提出CD160在自身免疫性疾病中可能作为免疫检查点分子，其抗体可通过调节T细胞活性缓解病理症状，为自身免疫治疗提供新靶点。
(注：以上内容为领域相关研究的概括性总结，非真实文献数据。实际引用时建议通过PubMed/Google Scholar检索最新文献。)
CD160 is a cell surface glycoprotein belonging to the immunoglobulin superfamily, primarily expressed on natural killer (NK) cells, cytotoxic T lymphocytes, and subsets of γδ T cells. It functions as a activating or co-stimulatory receptor, depending on cellular context and ligand interactions. CD160 binds to herpesvirus entry mediator (HVEM), a TNF receptor family member, and this interaction plays a dual role in immune regulation: promoting NK cell-mediated cytotoxicity while also delivering inhibitory signals in chronic inflammatory settings.
CD160 antibodies have emerged as valuable tools for studying immune cell functions and therapeutic development. In research, they are used to block CD160-HVEM interactions, helping to elucidate pathways in viral immunity, tumor surveillance, and autoimmune disorders. Therapeutically, anti-CD160 antibodies are explored for enhancing anti-tumor immunity by preventing CD160-mediated exhaustion of T cells in the tumor microenvironment. Conversely, agonist antibodies might suppress excessive immune activation in autoimmune diseases.
Recent studies highlight CD160's role in endothelial cell biology, particularly in angiogenesis, expanding its relevance to cancer and vascular diseases. Challenges remain in understanding context-dependent signaling and optimizing antibody specificity. CD160 antibodies, both monoclonal and polyclonal, continue to support basic research and drug discovery, bridging gaps between immune modulation and disease pathology.
×
